A New Therapeutic Molecule Type - Bispecific ADC
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody covalently attached to a payload via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs.
ADC is undergoing rapid development, and many companies are constantly innovating on targets, linkers, and payloads, such as bispecific ADC, dual-payload ADC, etc.
The New Molecule type - Bispecific ADC
Structure
Bispecific ADC involve a combination of ADC and bispecific antibodies. It is mainly divided into two types: one is targeting two different targets; the other is targeting two epitopes of the same target.
Advantages & Limitations
Unlike traditional ADC, BsADC has unique advantages[1]:
1. Reduce the occurrence of drug resistance;
2. Enhance specific targeting to improve safety;
3. Collaborative endocytosis can improve the efficiency of toxins entering target cells, thereby achieving improved therapeutic effects.
Currently, the highest status of BsADC is in clinical phase II
The limitation of development of BsADC include:
1. the difficulty of the process development;
2. the limited number of antibody skeleton molecules that can be used to construct BsADC;
3. the limitation of available targets for BsADC.
Therefore, the development of BsADC faces both opportunities and challenges.
ChemExpress Assists in Developing ADC—You Have Ideals, Let’s Do It!
ChemExpress is one of the earliest companies in China to conduct ADC research, providing an integrated ADC service platform. We can not only provide a rich range of payloads, linkers, payload-linkers, but also provide services such as process optimization, process validation, registration declaration, GMP industrialization, and customized services.
Reference:
[1] Drug Discovy Today Technol. 2018, 30, 55-61.
[2] https://www.biocytogen.com.cn/
[3] Websites of each company